SpyGlass Pharma, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
SGP Nasdaq 2830 www.spyglasspharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for SpyGlass Pharma, Inc.

SpyGlass Pharma Appoints Shannon Treviño as General Counsel - Jun 15th, 2026 6:00 am
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing - Jun 2nd, 2026 6:00 am
SpyGlass Pharma to Participate in Upcoming Investor Conferences - May 21st, 2026 6:00 am
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System - May 18th, 2026 6:00 am
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates - May 14th, 2026 2:05 pm
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update - Mar 26th, 2026 2:05 pm
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System - Mar 9th, 2026 6:00 am
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit - Mar 4th, 2026 6:00 am
MongoDB downgraded, Block upgraded: Wall Street's top analyst calls - Mar 3rd, 2026 7:33 am
SpyGlass Pharma Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares - Feb 9th, 2026 2:05 pm
Sector Update: Health Care Stocks Rise Late Afternoon - Feb 6th, 2026 1:50 pm
Sector Update: Health Care Stocks Rise in Afternoon Trading - Feb 6th, 2026 11:51 am
SpyGlass Pharma Announces Pricing of Initial Public Offering - Feb 5th, 2026 5:00 pm